NCT01362244 - Mepolizumab in Nasal Polyposis | Biotech Hunter

Enrollment

109

Participants

Timeline

Start Date

May 12, 2009

Primary Completion Date

December 5, 2014

Study Completion Date

December 5, 2014

Conditions

Nasal Polyps

Interventions

DRUG

Mepolizumab

750 mg of mepolizumab by IV infusion

DRUG

Placebo

Placebo by IV infusion

DRUG

Run In Medication

subjects will undergo a run-in period of 10 - 14 days on a low dose of Intranasal Steroids (INS).

Trial Locations (6)

GSK Investigational Site, Ghent

GSK Investigational Site, Amsterdam

GSK Investigational Site, Cambridge

GSK Investigational Site, London

GSK Investigational Site, London

GSK Investigational Site, London